Wie hoch ist der Preis für Altamira Therapeutics Ltd. (CYTO)

Preis für Altamira Therapeutics Ltd. (CYTO) ist $0.3

Wie hoch ist die Marktkapitalisierung für Altamira Therapeutics Ltd. (CYTO)

Marktkapitalisierung für Altamira Therapeutics Ltd. (CYTO) ist $1.13M

Altamira Therapeutics Ltd. (CYTO) Aktiensplits

Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.

Jahr	Aktien-Split	Multiplikator	Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.

Jahr

Aktien-Split

Multiplikator

Kumulierter Multiplikator

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Anzahl der Aktiensplits	Kumulierter Multiplikator	Land
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Unternehmen

Anzahl der Aktiensplits

Kumulierter Multiplikator

Land